- Home
- MNOV vs RTB Comparison
MNOV vs RTB Comparison
Compare MNOV & RTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | RTB |
|---|---|---|
| Founded | 2000 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.8M | 128.6M |
| IPO Year | 2004 | 2008 |
Fundamental Metrics
Financial Performance| Metric | MNOV | RTB |
|---|---|---|
| Price | $1.46 | $6.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.25 | N/A |
| AVG Volume (30 Days) | ★ 57.5K | 32.2K |
| Earning Date | 11-16-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,360,807.00 | ★ $11,131,000.00 |
| Revenue This Year | $78.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 194.15 | N/A |
| 52 Week Low | $1.22 | $6.58 |
| 52 Week High | $3.90 | $20.75 |
Technical Indicators
Market Signals| Indicator | MNOV | RTB |
|---|---|---|
| Relative Strength Index (RSI) | 42.72 | 32.98 |
| Support Level | $1.28 | N/A |
| Resistance Level | $1.54 | $9.00 |
| Average True Range (ATR) | 0.06 | 0.80 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 51.25 | 13.65 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
About RTB RTB Digital Inc. Common Stock
RTB Digital Inc is focused on developing and operating a professional SaaS (Software as a Service) platform that hosts an exclusive coalition of professionally managed online media channels. Its operations include software development, advertising and sponsorship sales, and onboarding third-party content operators (Platform Partners) to publish content on the platform.